Stromelysin-1 promoter 5A/6A polymorphism is an independent genetic prognostic risk factor and interacts with smoking cessation after index premature

被引:14
作者
Liu, PY
Li, YH
Tsai, WC
Tsai, LM
Chao, TH
Wu, HL
Chen, JH
机构
[1] Natl Cheng Kung Univ, Div Cardiol, Dept Internal Med, Med Ctr, Tainan 704, Taiwan
[2] Natl Cheng Kung Univ, Inst Clin Med, Tainan, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Dept Biochem, Tainan, Taiwan
关键词
acute myocardial infarction; matrix metallo-proteinase; polymorphism; prognosis; smoking cessation; stromelysin-1;
D O I
10.1111/j.1538-7836.2005.01515.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the prognostic roles of multiple polymorphisms and smoking cessation for premature myocardial infarction (MI). Methods: We studied 170 patients with MI onset before the age of 45 years (range 27-45 years, 84% men) and analyzed the traditional risk factors and several candidate genes' associations with their subsequent coronary events. Results: Follow-up data were available for a total of 162 individuals (95.3%) with the other 38 individuals (4.7%) being lost-to-follow-up premature MI patients. During a mean period of 4.43 years' follow-up, diabetes mellitus (DM), hypertension, hypercholesterolemia and Killip's status >= II were more frequent among patients with subsequent cardiac events (all P-values < 0.05). The frequency of 5A allele of stromelysin-1 gene was significantly higher among event group (P = 0.01). Smoking cessation after MI, use of beta-blocker or angiotensin-converting enzyme inhibitor (ACEI) could improve outcome (all P-values < 0.05). After multivariate analysis, we found that DM was an independent risk factor for survival [Hazard ratio (HR) 2.45, P = 0.01]. Successful smoking cessation and therapy with ACEI could have a protective effect (HR 0.33 and 0.09, P = 0.01 and < 0.01. respectively). The stromelysin-1 5A gene polymorphism was also an independent survival predictor (HR 22.51, P = 0.03). In addition, smoking cessation could significantly modify the risk, especially among patients with 5A allele polymorphism (HR 6.75 vs. 1.50). Conclusion: We thus conclude that the stromelysin-1 gene polymorphism alone or in combination with smoking cessation can influence the prognosis after index premature MI.
引用
收藏
页码:1998 / 2005
页数:8
相关论文
共 39 条
[21]   Synergistic effect of stromelysin-1 (matrix metalloproteinase-3) promoter 5A/6A polymorphism with smoking on the onset of young acute myocardial infarction [J].
Liu, PY ;
Chen, JH ;
Li, YH ;
Wu, HL ;
Shi, GY .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (01) :132-139
[22]  
Margaglione M, 1997, THROMB HAEMOSTASIS, V77, P605
[23]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[24]   Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis [J].
Rauramaa, R ;
Väisänen, SB ;
Luong, LA ;
Schmidt-Trücksäss, A ;
Penttilä, IM ;
Bouchard, C ;
Töyry, J ;
Humphries, SE .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (12) :2657-2662
[25]   Pl(A1/A2) polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis [J].
Ridker, PM ;
Hennekens, CH ;
Schmitz, C ;
Stampfer, MJ ;
Lindpaintner, K .
LANCET, 1997, 349 (9049) :385-388
[26]   Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes - The Northern Manhattan Prospective Cohort Study [J].
Rundek, T ;
Elkind, MS ;
Pittman, J ;
Boden-Albala, B ;
Martin, S ;
Humphries, SE ;
Juo, SHH ;
Sacco, RL .
STROKE, 2002, 33 (05) :1420-1423
[27]   The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels [J].
Sacks, FM ;
Pfeffer, MA ;
Moye, LA ;
Rouleau, JL ;
Rutherford, JD ;
Cole, TG ;
Brown, L ;
Warnica, JW ;
Arnold, JMO ;
Wun, CC ;
Davis, BR ;
Braunwald, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1001-1009
[28]  
SHAH PK, 1995, CIRCULATION, V92, P1565
[29]  
SHARP DS, 1995, THROMB HAEMOSTASIS, V74, P730
[30]   PREVENTION OF CORONARY HEART-DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA [J].
SHEPHERD, J ;
COBBE, SM ;
FORD, I ;
ISLES, CG ;
LORIMER, AR ;
MACFARLANE, PW ;
MCKILLOP, JH ;
PACKARD, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (20) :1301-1307